I-Therapeutix (Waltham, MA) a development-stage medical device company focused on a synthetic ocular bandage for ophthalmic surgery, closed a $15M Series C financing. Participants include Polaris Venture Partners, Versant Ventures and SV Life Sciences.

Apieron (Menlo Park, CA) a commercial-stage medical device company and developer of an exhaled nitric oxide monitor for the management of asthma, closed a $XM Series D financing. Participants include Onset Ventures, Alliance Technology Ventures, Canaan Partners and Draper Fisher Jurvetson.

*Investment amt undisclosed by by company

Transcend Medical (Menlo Park, CA) a research and development stage medical device company focused on minimally invasisve treatment of glaucoma, closed a $35M Series B financing. Participants include HLM Venture Partners, Canaan Partners, Latterell Venture Partners, Technology Partners, Morgenthaler Ventures and Split Rock Partners.

LifeBond (Israel) a commercial-stage developer of wound-closure and hemostasis biomaterials, closed a $8M Series B financing. Participants include Pitango Venture Capital, GlenRock Israel and The Zitelman Group.

Xanodyne Pharmaceuticals (Newport, KY) an clinical-stage specialty pharmaceutical company focused on pain and menorrhagia, closed a $38M Series D financing. Participants include MPM Capital, AIG Investments, Aisling Capital, Blue Chip Venture Company, Essex Woodlands Health Ventures, HealthCare Ventures and Union Springs Pharmaceuticals.

miRagen Therapeutics (Boulder, CO) a preclinical-stage biopharmaceutical company focused on the development of miRNA therapeutics for cardiovascular and muscle diseases, closed a $4 Series B, bringing the total round financing to $12M. Participants include Boulder Ventures, Amgen Ventures, Broadview Ventures, The Peierls Foundation and Atlas Venture.

Estech (San Ramon, CA) a commercial-stage developer, manufacturer and distributor of cardiac surgery devices closed a $8M Series C financing. Participants include NBGI Ventures, Saints Capital Everest, Telegraph Hill Partners and Waveland Venture Partners.

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

HCL Clean Tech (Israel) an early-stage biofuels company working to convert lignocellulosic biomass to fermentable sugars, closed a $5.5M Series A financing. Participants include Burrill & Co. and Khosla Ventures.
*Investment amt undisclosed by company

Pathway Medical Technologies (Kirkland, WA) development-stage medical company focused on peripheral-arterial disease, closed a $42.5M Series D financing. Participants include HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners, Forbion Capital Partners, Giza Venture Capital and WRF Capital.

Sagent Pharmaceuticals (Schaumberg, Illinois) commercial-stage specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products, closed a $30M Series A financing, bringing the total round to $113M. Participants include Vivo Ventures.

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $4.6M Series B financing, bringing the total round to $27.5M. Participants include Roche Venture Fund, Enterprise Ireland, Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.